APIXABAN — REGCON HOLDINGS, approved 2022-06-17 (ANDA209898).
37,282 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.